<DOC>
	<DOCNO>NCT00440648</DOCNO>
	<brief_summary>This double-blind , randomize , cross-over study conduct center within United States . The study consist five period : two-week Screening Period , 5-week Run-In Period , two eight-week study treatment period two-week Washout Period . Patients assign randomly ( 1:1 ) one two treatment sequence : sevelamer carbonate eight week follow sevelamer hydrochloride eight week sevelamer hydrochloride eight week follow sevelamer carbonate eight week</brief_summary>
	<brief_title>Cross-Over Study Sevelamer Hydrochloride Sevelamer Carbonate</brief_title>
	<detailed_description>The study conduct 15 center ( 2 enroll patient ) . A total 79 hemodialysis patient assign randomly one two treatment sequence .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Sevelamer</mesh_term>
	<criteria>patient receive hemodialysis three time per week 3 month longer ; patient maintain sevelamer hydrochloride primary phosphate binder total daily dose ≤ 13.6 g serum phosphorus concentration last two measurement 3.0 6.5 mg/dL , recent iPTH ≤ 600 pg/mL recent serum calcium within normal range . patient active bowel obstruction , dysphagia , swallow disorder , severe gastrointestinal motility disorder ; active ethanol drug abuse ( exclude tobacco ) ; need antidysrhythmic antiseizure medication use control condition ; poorly control diabetes mellitus hypertension ; active vasculitis ; active malignancy basalcell carcinoma ; HIV infection ; clinically significant unstable medical condition judge Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>